Interested Persons

Return to CIRM Meetings and Events

 

Institute of Medicine
Committee on a Review of the California Institute for Regenerative Medicine

Location

Arnold and Mabel Beckman Center
of the National Academies of Sciences and Engineering
Huntington Room
100 Academy
Irvine, CA 92617

Date

April 10, 2012

Audiocast details

The meeting audiocast will be linked from the National Academy of Science’s home page: www.nationalacademies.org

Draft Agenda
 

PUBLIC WORKSHOP

9:00 a.m. WELCOME AND COMMITTEE INTRODUCTIONS
Harold T. Shapiro, Ph.D.
IOM Committee Chair

9:10 a.m. OVERVIEW OF LITTLE HOOVER COMMISSION REPORT
Stuart Drown (by phone)
Executive Director
Little Hoover Commission

10:00 a.m. PERSPECTIVES ON CIRM FROM STAKEHOLDERS

Ruth Holton-Hodson
California Deputy State Controller

Ken Taymor, J.D. (by phone)
Executive Director
Berkeley Center for Law, Business and Economy

John Simpson (by phone)
Director, Stem Cell Oversight and Accountability Project
Consumer Watchdog

Marcy Darnovsky, PhD (by phone) 
Associate Executive Director Center for Genetics and Society

David Jensen
Publisher-Editor
California Stem Cell Report

11:30 a.m. LUNCH

12:00 p.m. PERSPECTIVES FROM CIRM APPLICANTS

Leonard H. Rome, Ph.D. (by phone) Senior Associate Dean for Research Professor of Biological Chemistry David Geffen School of Medicine at UCLA

Xuejun H. Parsons, Ph.D. Associate Professor of Regenerative Medicine, Scientific Director in Cardiovascular and Neural Regeneration, San Diego Regenerative Medicine Institute

12:45 p.m. PERSPECTIVES ON CIRM FROM DISEASE TEAM INVESTIGATORS

Donald Kohn, M.D.
Professor, Department of Microbiology, Immunology, and Molecular Genetics and Department of Pediatrics, University of California, Los Angeles

Larry Goldstein, Ph.D. Professor
Department of Cellular and Molecular Medicine Department of Neurosciences UC San Diego School of Medicine

Dennis Clegg, Ph.D.
Professor, Molecular, Cellular, and Developmental Biology University of Southern California

Catriona Jamieson, M.D., Ph.D.
Associate Professor, Division of Hematology-Oncology UC San Diego Moores Cancer Center

2:00 p.m. PERSPECTIVES ON CIRM FROM INDUSTRY

Gregory A. Bonfiglio, J.D., Panel Moderator 
Managing Partner, Proteus Venture Partners

Michael D. West, Ph.D.
Chief Executive Officer, BioTime, Inc.

Allan Robins, Ph.D.
Acting Chief Executive Officer, Vice President and Chief Technical Officer, ViaCyte, Inc.

Gail K. Naughton, Ph.D.
CEO, Chairman of the Board, Histogen, Inc.

3:30 p.m. BREAK

3:45 p.m. PERSPECTIVES ON CIRM FROM TECHNOLOGY TRANSFER OFFICERS

Casie Kelly, Ph.D. Technology Transfer Officer, Life Sciences
Office of Intellectual Property & Industry Sponsored Research, University of California, Los Angeles

4:30 p.m. PUBLIC COMMENT

Individuals register for a slot and have 5 minutes for comments on any topic related to the study charge.

5:30 p.m. ADJOURN OPEN SESSION


Date Published: October 9, 2012